TEYI PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.38 CNY | -1.78% |
|
-18.33% | -26.72% |
| 04-19 | Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-29 | Teyi Pharmaceutical Group Co.,Ltd Approves the Cash Dividend for 2023 | CI |
| Sales 2024 * | 1.16B 161M 220M | Sales 2025 * | 1.38B 190M 260M | Capitalization | 4.79B 662M 903M |
|---|---|---|---|---|---|
| Net income 2024 * | 285M 39.36M 53.74M | Net income 2025 * | 361M 49.86M 68.08M | EV / Sales 2024 * | 4.11 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.48 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
13.3
x | Employees | 1,243 |
| Yield 2024 * |
4.49% | Yield 2025 * |
4.03% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.78% | ||
| 1 week | -18.33% | ||
| Current month | -17.25% | ||
| 1 month | -18.64% | ||
| 3 months | -18.59% | ||
| 6 months | -23.38% | ||
| Current year | -26.72% |
1 week
9.19
10.33
1 month
9.1911.71
Current year
8.2513.29
1 year
8.2517.49
3 years
5.6419.64
5 years
5.0119.64
10 years
4.6523.05
| Managers | Title | Age | Since |
|---|---|---|---|
Dan Qing Xu
CEO | Chief Executive Officer | 55 | 09-06-14 |
Xi Liang Chen
DFI | Director of Finance/CFO | 52 | 09-06-14 |
Wei Cheng Wu
BRD | Director/Board Member | 55 | 18-11-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Qing Xu
CEO | Chief Executive Officer | 55 | 09-06-14 |
Song Qing Xu
BRD | Director/Board Member | 54 | 09-06-14 |
Xi Liang Chen
DFI | Director of Finance/CFO | 52 | 09-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 9.38 | -1.78% | 23,734,060 |
| 24-04-25 | 9.55 | +0.84% | 16,346,960 |
| 24-04-24 | 9.47 | -6.50% | 21,794,520 |
| 24-04-23 | 10.13 | -2.00% | 23,052,329 |
| 24-04-22 | 10.34 | -10.01% | 41,342,251 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
TEYI PHARMACEUTICAL GROUP CO., LTD, formerly Guangdong Taicheng Pharmaceutical Co., Ltd., is principally engaged in the production and sale of pharmaceuticals. The Company primarily provides Chinese traditional patent medicines, including cough arresting and phlegm removing medicine series, kidney reinforcing medicine series and anti-infection medicine series, among others. The Company's products mainly include tablets, granules, medicinal tea, syrup, decocted extracts, capsules, powder, ointment, cream, as well as oral solutions, among others.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.38
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.72% | 661M | |
| +25.83% | 661B | |
| +26.79% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.53% | 231B | |
| +5.30% | 200B | |
| -8.92% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002728 Stock
